Stock MCOV B MEDICOVER AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medicover AB

Equities

MCOV B

SE0009778848

Healthcare Facilities & Services

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:44 2024-04-26 am EDT 		5-day change 1st Jan Change
161 SEK +23.28% Intraday chart for Medicover AB +22.71% +7.26%
Apr. 26 Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest DJ
Apr. 26 Transcript : Medicover AB, Q1 2024 Earnings Call, Apr 26, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,383 2,413 5,364 1,868 2,017 2,059 - -
Enterprise Value (EV) 1 1,800 2,694 5,853 2,759 2,961 3,080 3,187 3,310
P/E ratio 61.8 x 89.4 x 52.7 x 155 x 114 x 80.9 x 38.2 x 26.5 x
Yield 0.48% 0.43% 0.33% 0.96% 0.89% 0.87% 0.97% 1.31%
Capitalization / Revenue 1.64 x 2.42 x 3.89 x 1.24 x 1.16 x 1.02 x 0.88 x 0.76 x
EV / Revenue 2.13 x 2.7 x 4.25 x 1.83 x 1.7 x 1.53 x 1.37 x 1.23 x
EV / EBITDA 14.9 x 17.1 x 21.6 x 12.7 x 12.1 x 10.7 x 9.23 x 8.12 x
EV / FCF -138 x 32.3 x 51.1 x 93.2 x 31.3 x 33.5 x 26.1 x 22.8 x
FCF Yield -0.72% 3.1% 1.96% 1.07% 3.19% 2.99% 3.83% 4.38%
Price to Book 4.36 x 5.39 x 10.6 x 4.01 x 4.17 x 4.12 x 3.84 x -
Nbr of stocks (in thousands) 133,335 148,335 148,335 148,938 149,652 149,671 - -
Reference price 2 10.37 16.27 36.16 12.54 13.48 13.75 13.75 13.75
Announcement Date 2/14/20 2/12/21 2/11/22 2/17/23 2/9/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 844.4 997.8 1,377 1,510 1,746 2,018 2,334 2,692
EBITDA 1 120.7 157.5 270.4 217.4 243.8 287.4 345.5 407.5
EBIT 1 46.5 61.3 159.4 55.5 61.4 90.94 135 177.8
Operating Margin 5.51% 6.14% 11.57% 3.68% 3.52% 4.51% 5.78% 6.6%
Earnings before Tax (EBT) 1 33.3 37.3 143.8 19.8 23.6 35.86 83.23 134.3
Net income 1 22.5 25.8 101.8 12.1 17.6 23.13 54.37 95.7
Net margin 2.66% 2.59% 7.39% 0.8% 1.01% 1.15% 2.33% 3.55%
EPS 2 0.1680 0.1820 0.6860 0.0810 0.1180 0.1700 0.3600 0.5200
Free Cash Flow 1 -13 83.5 114.5 29.6 94.5 92 122 145
FCF margin -1.54% 8.37% 8.31% 1.96% 5.41% 4.56% 5.23% 5.39%
FCF Conversion (EBITDA) - 53.02% 42.34% 13.62% 38.76% 32.01% 35.31% 35.58%
FCF Conversion (Net income) - 323.64% 112.48% 244.63% 536.93% 397.69% 224.37% 151.52%
Dividend per Share 2 0.0500 0.0700 0.1200 0.1200 0.1200 0.1200 0.1333 0.1800
Announcement Date 2/14/20 2/12/21 2/11/22 2/17/23 2/9/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 376.3 381.7 362.2 368.6 397.7 419.3 424.7 440.5 461.9
EBITDA 75.1 67.5 56.2 48.8 - 54.3 61.1 67.1 -
EBIT 41.6 22.5 15.2 9.1 8.7 10.7 13.2 18.5 -
Operating Margin 11.06% 5.89% 4.2% 2.47% 2.19% 2.55% 3.11% 4.2% -
Earnings before Tax (EBT) 1 37.5 17.1 4 -4.2 - 3 9.7 0.5 10.4
Net income 27.5 12.2 1.6 -3.6 - 1.5 5.5 - -
Net margin 7.31% 3.2% 0.44% -0.98% - 0.36% 1.3% - -
EPS - 0.0820 0.0110 -0.0240 - - - - -
Dividend per Share - - - - - - - - -
Announcement Date 2/11/22 4/27/22 7/22/22 11/3/22 2/17/23 4/27/23 7/26/23 11/3/23 2/9/24
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 417 281 489 891 944 1,022 1,129 1,252
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.452 x 1.782 x 1.81 x 4.098 x 3.872 x 3.555 x 3.267 x 3.071 x
Free Cash Flow 1 -13 83.5 115 29.6 94.5 92 122 145
ROE (net income / shareholders' equity) 7.14% 6.74% 21.1% 2.44% 3.6% 3.85% 10.1% 19.4%
ROA (Net income/ Total Assets) - 2.42% 7.28% - - - - -
Assets 1 - 1,067 1,398 - - - - -
Book Value Per Share 2 2.380 3.020 3.410 3.120 3.230 3.340 3.580 -
Cash Flow per Share 0.6500 1.050 1.460 - - - - -
Capex 1 63.2 72.5 102 141 111 117 188 210
Capex / Sales 7.48% 7.27% 7.42% 9.31% 6.33% 5.82% 8.06% 7.81%
Announcement Date 2/14/20 2/12/21 2/11/22 2/17/23 2/9/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Medicover AB

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.75 EUR
Average target price
16.58 EUR
Spread / Average Target
+20.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
MEDICOVER AB Stock Medicover AB
+7.26% 2.2B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+11.62% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. MCOV B Stock
  4. Financials Medicover AB